| (Values in U.S. Thousands) | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2018 |
| Sales | 3,800 | 5,070 | 4,150 | 140 | 190 |
| Sales Growth | -25.05% | +22.17% | +2,864.27% | -26.32% | -53.66% |
| Net Income | -11,420 | -7,480 | -6,860 | -3,480 | -3,940 |
| Net Income Growth | -52.67% | -9.04% | -97.13% | +11.68% | -33.56% |
Stagezero Life Sciences Ltd (SZLSF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
StageZero Life Sciences Ltd is dedicated to the early detection of cancer and multiple disease states through whole blood. The company's test consists of Aristotle(R), a multi-cancer panel for simultaneously screening for cancers from a single sample of blood. StageZero Life Sciences Ltd, formerly known as GeneNews Ltd., is based in TORONTO, ON.
Fiscal Year End Date: 12/31